Top 5 liver cancer stories in 2021

This year, in the area of ​​liver cancer, CURE® has covered important Food and Drug Administration (FDA) approvals, side effect management, and various treatment options and strategies for patients, among a multitude of other subjects.

We’ve reviewed our most read liver cancer content from 2021 and compiled it for our audience as follows:

1. FDA approves radiation therapy for outpatient treatment of liver cancer subtype

In March, the Food and Drug Administration approved Therasphere ™ Yttrium-90 (Y-90) glass microspheres – a type of radiation therapy – for patients with hepatocellular carcinoma (HCC). The minimally invasive procedure is the only radioembolization treatment currently approved in the United States for these patients.

2. Tag Teaming Liver Cancer Care

In its “Speaking Out” video series, CURE® discussed the basics of liver cancer and the importance of a multidisciplinary approach to care with Dr. Laura M. Kulik of the Feinberg School of Medicine at Northwestern University. “It’s like … a soccer team. Instead of having 11 players in the squad on the pitch, if you only have five players on the pitch, you won’t do as well in this game.” , Kulik explained.

3. The neoadjuvant Libtayo shows promise for patients with hepatocellular carcinoma

In the results of a phase 2a study presented at the 2021 annual meeting of the American Association for Cancer Research, pre-surgical Libtayo (cemiplimab-rwlc) given to patients with resectable HCC led to 20% of patients experience significant cell death, called tumor necrosis.

4. Side effects of immune checkpoint inhibitors may increase hospital admissions and costs for patients with bladder, liver, lung or skin cancer.

Recently published results showed that patients with liver cancer who received treatment with immune checkpoint inhibitors and suffered side effects as a result were at higher risk of hospitalizations, visits. emergencies and higher health care costs than patients who had no side effects.

5. Underutilized non-invasive bridging therapy compared to more invasive options in hepatocellular carcinoma eligible for transplantation

External beam radiation therapy – a non-invasive bridging therapy option – is underused in HCC patients awaiting liver transplants compared to other liver-directed therapies, study results show presented at the American Society for Radiation Oncology Annual Meeting.

For more information on cancer updates, research and education, be sure to subscribe to CURE® newsletters here.


Source link

Comments are closed.